Vera Therapeutics, Inc. (VERA)
| Previous close | 38.69 |
| Open | 38.75 |
| Bid | 39.73 x 100 |
| Ask | 40.19 x 100 |
| Day's range | 38.40 - 40.25 |
| 52-week range | 6.07 - 50.78 |
| Volume | |
| Avg. volume | 1,180,764 |
| Market cap | 2.178B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.25 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.88 |
GuruFocus.comInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
Vera Therapeutics Inc (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, has reported an insider sale according to a recent SEC filing.
- Yahoo Finance Video
Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal
Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
